Oxford Immunotec Global

Oxford Immunotec Global Ltd. operates as a diagnostics company, which develops and commercializes proprietary tests for immunology and infectious disease. Its products include T-SPOT.TB, T-SPOT.CMV, T-SPOT.PRT and T-CELL XTEND. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom.

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global diagnostics company, today announced second quarter 2020 financial results.

Oxford Immunotec Reports Second Quarter 2020 Financial Results

Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Oxford Immunotec (OXFD) Q2 Earnings Expected to Decline

OXFORD, United Kingdom and MARLBOROUGH, Mass., July  21, 2020  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2020 financial results before the open of the market on Tuesday, August 4, 2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.

Oxford Immunotec Schedules Second Quarter 2020 Earnings Release and Conference Call for August 4, 2020

OXFORD, United Kingdom and MARLBOROUGH, Mass., July  20, 2020  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), today announced that it has entered into a long-term agreement to supply its T-SPOT.TB test and associated accessories to the Stop TB Partnership - Global Drug Facility (GDF). This follows the inclusion of the T-SPOT.TB test in the GDF’s diagnostics catalog for the detection of tuberculosis (TB) infection.

Oxford Immunotec Announces Agreement with Stop TB Partnership - Global Drug Facility (GDF) to Provide Access to the T-SPOT®.TB Test for 100+ TB Burden Countries

Oxford Immunotec Global PLC's (OXFD) CEO Peter Wrighton-Smith on Q1 2020 Results - Earnings Call Transcript

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Oxford Immunotec (OXFD) Reports Q1 Loss, Lags Revenue Estimates

Shares of Oxford Immunotec Global (NASDAQ:OXFD) remained unaffected at $11.76 after the company reported Q1 results.

Recap: Oxford Immunotec Global Q1 Earnings

OXFORD, United Kingdom and MARLBOROUGH, Mass., April  21, 2020  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it has successfully obtained re-registration of the T-SPOT.TB test in China.  The re-registration was granted by the Chinese National Medical Products Administration (NMPA) on April 13, 2020 and, as is customary, the registration lasts until April 12, 2025 whereupon it will need to be renewed.

Oxford Immunotec announces successful re-registration of the T-SPOT®.TB test in China

Oxford Immunotec Global PLC's (OXFD) CEO Peter Wrighton-Smith on Q4 2019 Results - Earnings Call Transcript

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 45.45% and 4.80%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Oxford Immunotec (OXFD) Reports Q4 Loss, Tops Revenue Estimates

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb.  20, 2020  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announces two ground-breaking publications in Clinical Infectious Diseases (CID) on the performance of T-SPOT.CMV; a test for measuring the strength of a patient’s cellular immune response to Cytomegalovirus (CMV) in kidney and stem cell transplant.  Increased response in the T-SPOT.CMV test is associated with protection against CMV infection.  Application of the test raises the prospect of improved, individualized management of CMV infection risk in transplant recipients. 

Oxford Immunotec Announces New Data on the Utility of T-SPOT®.CMV in Kidney and Stem Cell Transplant

Oxford Immunotec Global is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Oxford Immunotec Global Stock: Moving Average Crossover Alert

Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q3 2019 Results - Earnings Call Transcript

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 180.00% and 4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Oxford Immunotec (OXFD) Q3 Earnings and Revenues Surpass Estimates

Will Oxford Immunotec (OXFD) Report Negative Earnings Next Week? What You Should Know

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug.  21, 2019  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), or the Company, a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will be participating in two upcoming investor conferences.

Oxford Immunotec to Participate in Two Upcoming Investor Conferences

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 140.00% and 0.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Oxford Immunotec (OXFD) Beats Q2 Earnings and Revenue Estimates

Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q1 2019 Results - Earnings Call Transcript

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 70.00% and 6.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Oxford Immunotec (OXFD) Reports Q1 Loss, Tops Revenue Estimates

Oxford Immunotec (OXFD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Oxford Immunotec (OXFD) a New Buy Stock

Oxford Immunotec Global PLC (OXFD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Oxford Immunotec Global

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 757.89% and -17.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

News for Oxford Immunotec Global Stock (OXFD)